Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years
/PRNewswire/ Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key.
The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued a joint statement in response to the new research on aortic valve replacement in low-risk patients announced during the Transcatheter Cardiovascular Therapeutics Conference, TCT 2023, and recently published in The Annals of Thoracic Surgery.